Key result
Trastuzumab emtansine combined with pertuzumab yielded an overall objective response rate of 41% in patients with HER2-positive locally advanced or metastatic breast cancer.
Why the study?
Does the combination of trastuzumab emtansine and pertuzumab improve objective response rate in patients with HER2-positive locally advanced or metastatic breast cancer?
Does the combination of trastuzumab emtansine and pertuzumab improve objective response rate in patients with HER2-positive locally advanced or metastatic breast cancer?
Answers are grounded in this paper and cite their sources.
The combination of trastuzumab emtansine and pertuzumab demonstrated preliminary efficacy and manageable toxicity in patients with HER2-positive metastatic breast cancer.
PURPOSE: Our phase IIa study characterized the safety and efficacy of two human epidermal growth factor receptor 2 (HER2) -targeted agents, trastuzumab emtansine (T-DM1) and pertuzumab, in patients with HER2-positive metastatic breast cancer (MBC). PATIENTS AND METHODS: Patients with HER2-positive locally advanced breast cancer or MBC were treated with 3.6 mg/kg T-DM1 plus pertuzumab (840-mg loading dose, then 420 mg subsequently) once every 3 weeks. The primary efficacy end point was investigator-assessed objective response rate (ORR). RESULTS: Sixty-four patients (43 patients in the second-line or greater setting [advanced MBC]; 21 patients in the first-line setting [first-line MBC]) were enrolled. Patients with advanced MBC had received trastuzumab and a median of six prior nonhormonal treatments for MBC; 86% of first-line MBC patients had received trastuzumab in the (neo)adjuvant setting. The ORR was 41% overall, 33% in patients with advanced MBC, and 57% in first-line patients. Median progression-free survival was 6.6, 5.5, and 7.7 months, respectively. The most common adverse events were fatigue (61%), nausea (50%), and diarrhea (39%). The most frequent grade ≥ 3 adverse events were thrombocytopenia (13%), fatigue (11%), and liver enzyme elevations (increased ALT: 9%; increased AST: 9%). One patient had left ventricular ejection fraction of less than 40% after study drug discontinuation. Exploratory biomarker analyses demonstrated that patients with above-median tumor HER2 mRNA levels had a numerically higher ORR than patients with below-median levels (44% v 33%, respectively). CONCLUSION: T-DM1 and pertuzumab can be combined at full doses with no unexpected toxicities. The preliminary efficacy in patients in the first-line and advanced MBC settings warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2014) studied HER2-positive locally advanced or metastatic breast cancer (n=64). Trastuzumab emtansine (T-DM1) and pertuzumab was evaluated on investigator-assessed objective response rate (ORR). Trastuzumab emtansine combined with pertuzumab yielded an overall objective response rate of 41% in patients with HER2-positive locally advanced or metastatic breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: